Uptake of radiolabeled morphiceptin and its analogs by experimental mammary adenocarcinoma: in vitro and in vivo studies.

@article{Mirowski2004UptakeOR,
  title={Uptake of radiolabeled morphiceptin and its analogs by experimental mammary adenocarcinoma: in vitro and in vivo studies.},
  author={Marek Mirowski and Rafał Wiercioch and Anna Janecka and Ewa Balcerczak and Ewa Byszewska and Gary Birnbaum and Sz Byzia and Piotr Garnuszek and Ryszard Wierzbicki},
  journal={Nuclear medicine and biology},
  year={2004},
  volume={31 4},
  pages={451-7}
}
Morphiceptin (Tyr-Pro-Phe-Pro-NH(2)) and its analogs modified at position 3: [D-Phe(3)]morphiceptin, [D-ClPhe(3)]morphiceptin and [D-Cl(2)Phe(3)]morphiceptin were synthesized and labeled with [(125)I] or [(131)I]. Their binding to membranes isolated from experimental adenocarcinoma was examined in vitro with the use of a cross-linking assay followed by the Western blot technique. The radioactive complex had molecular weight of about 65 kDa and was detectable by anti-mu-opioid receptor… CONTINUE READING